Ocugen, Inc. Announces Completion of Dosing in Subjects With Geographic Atrophy Secondary to Damd in High-Dose Cohort of Phase 1/2 Armada Clinical Trial of Ocu410—a Novel Modifier Gene Therapy
ocugen公司宣佈其Ocu410新型調節基因療法第一/二期Armada臨床試驗的高劑量組地理性萎縮患者的劑量已經完成。